The benefit of desmopressin (DDAVP) in the treatment of the urinary symptoms of multiple sclerosis has until now only been shown in short crossover studies of up to 6 weeks. We report 19 patient who have used the drug for an average of 2 years and 4 months, 18 of whom confirmed continued dramatic benefit without any obvious change in dosage used or efficacy and with few side effects. Ten of the 19 patienit had also used DDAVP during daytime for special occasions with notable success. This is the first study to suggest that DDAVP is safe and effective in long term use in MS.
Hilton P , Stanton SL. (1982) The use of desmospressin (DDAVP) in nocturnal urinary frequency in the female . Br J Urol54: 252-253 .
2.
Hilton P , Hertogs K , Stanton SL. (1993) The use of desmospressin (DDAVP) for nocturia in women with multiple sclerosis . J Neurol Neurosurg Psychiatry46: 854-855 .
3.
Kinn AC , Larsson PO. (1990) Desmopressin: A new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis . Scand J Urol Nephrol24: 109-112 .
4.
Valiquette G , Abrams GM , Herbert J. (1992) DDAVP in the management of nocturia in multiple sclerosis . Ann Neurol5: 577-577 .
5.
Fredrikson S. (1996) Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis . Acta Neurol Scand94: 31-34 .
6.
Valiquette G , Herbert J , Mcade-D'Alisera P. (1996) Desmopressin in the management of nocturia in patients with multiple sclerosis . Arch Neurol53: 1270-1275 .
7.
Hoverd P , Fowler C. (1998) Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis . J Neurol Neurosurg Psychiatry65: 778-780 .
